Leukapheresis Market Report 2026

The leukapheresis market size has grown strongly in recent years. It will grow from $72.02 billion in 2025 to $77.7 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to growth in hematologic disorders, expansion of cancer research programs, increasing use of apheresis in blood centers, advancements in centrifugation technologies, rising clinical research funding.

The leukapheresis market size is expected to see strong growth in the next few years. It will grow to $104.27 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to growth in car-t and cell-based therapies, increasing investment in immunology research, rising demand for personalized medicine, expansion of biopharmaceutical manufacturing, technological advancements in apheresis automation. Major trends in the forecast period include rising use of leukapheresis in cell and gene therapies, increasing demand for immune cell collection in oncology, growing adoption of automated apheresis systems, expansion of leukapheresis in clinical research, increasing focus on patient-safe disposable apheresis kits.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the leukapheresis market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body’s own healthy tissues. Reduced microbial exposure in early life and modern environmental factors are disrupting immune balance, contributing to the rise of these disorders. Leukapheresis helps manage autoimmune diseases by selectively removing harmful white blood cells that cause the immune system to attack the body. For example, in September 2025, according to GetValue.co, a US-based online digital platform, autoimmune diseases affect an estimated 3-10% of the global population, or roughly 600-800 million people worldwide. Consequently, the growing prevalence of autoimmune diseases is fueling the expansion of the leukapheresis market.

Major companies in the leukapheresis market are focusing on innovations such as GMP-grade leukopaks to improve the quality and efficiency of cell therapy manufacturing. GMP-grade leukopaks are leukapheresis-derived products processed under strict good manufacturing practice (GMP) standards, ensuring high viability and functionality of the collected cells for therapeutic use. For example, in November 2024, Sanguine Biosciences, a US-based biotechnology company, launched LeukoCer, a GMP-grade leukopak designed to streamline workflows and accelerate cell therapy development. LeukoCer provides high-quality starting materials in fresh whole or half packs, produced according to rigorous GMP standards, enabling researchers to advance their work and bring new cell therapies to market more efficiently.

In July 2023, SCTbio, a Czech Republic-based contract development and manufacturing organization, partnered with Cyto-care.eu GmbH to improve the cryopreservation process for cell therapy in Europe. The collaboration focuses on enhancing the collection, cryopreservation, quality control, and logistics of leukapheresis materials, which are essential for manufacturing advanced cell therapy products (ATMPs). Cyto-care.eu GmbH is an Austria-based company specializing in supplying cell products for biomedical research, drug discovery, and cell and gene therapy.

Major companies operating in the leukapheresis market are Fresenius Kabi, Grifols S.A., Terumo BCT Inc., Nikkiso Co., Haemonetics Corporation, Macopharma, MEDICA S.p.A, Caltag Medsystems Ltd., Miltenyi Biotec, Puriblood Medical, Cytopheron Technologies, STEMCELL Technologies Inc., Discovery Life Sciences, BioIVT LLC, StemExpress LLC, AllCells LLC, HemaCare Corporation, Key Biologics LLC, Immune Therapy Holdings AB, Cellsep Laboratories.

North America was the largest region in the leukapheresis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukapheresis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukapheresis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the leukapheresis market by increasing costs for imported apheresis devices, disposable kits, and precision centrifugation components. These impacts are most evident in therapeutic and research applications, particularly in North America, Europe, and Asia-Pacific regions with high device import dependence. Increased tariffs have raised procurement costs for hospitals, blood centers, and research institutes. Positively, tariffs have encouraged regional manufacturing of leukapheresis systems and improved supply chain localization.

The leukapheresis market research report is one of a series of new reports that provides leukapheresis market statistics, including leukapheresis industry global market size, regional shares, competitors with a leukapheresis market share, detailed leukapheresis market segments, market trends and opportunities, and any further data you may need to thrive in the leukapheresis industry. This leukapheresis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leukapheresis is a medical procedure in which white blood cells (leukocytes) are separated and removed from a person’s blood, while the remaining components, such as red blood cells and plasma, are returned to the body. This technique is employed to treat conditions with elevated white blood cell counts or to collect specific immune cells for research or therapeutic purposes.

The primary types of leukapheresis include granulocyte, lymphocyte, and monocyte apheresis. Granulocyte apheresis selectively isolates granulocytes (a type of white blood cell) from a patient’s blood for therapeutic use. Products involved include leukapheresis devices, centrifugal devices, membrane separators, and disposables. Applications cover research, cancer studies, immunology research, therapeutic treatments, hematologic disorders, autoimmune diseases, and more, and are utilized by blood component providers, blood centers, academic and research institutes, pharmaceutical and biotechnology companies, as well as hospitals and transfusion centers.

The leukapheresis market consists of revenues earned by entities providing services such as cell collection, cell processing and storage, and custom apheresis procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The leukapheresis market also includes sales of products such as apheresis machines, centrifugal and membrane-based systems, needles & catheters, and anticoagulants and solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.